FDA Drug Safety Podcasts
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Publishing Details
Contact & Outreach
About This Podcast
Explore Statistics
Recent Episodes
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
Listen to an audio podcast of the September 12th, 2024 FDA Drug Safety Communication on rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause.
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)
Listen to FDA Drug Safety Podcast titled, FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia…
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
Listen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1 RAs causes suicidal thoughts/actions.
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
Listen to an audio podcast of the November 28, 2023, FDA Drug Safety Communication, FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia…
FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
Listen to an audio podcast of the May 11, 2023, FDA Drug Safety Communication on warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use
Listen to an audio podcast of the April 13, 2023, FDA Drug Safety Communication, FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use.
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
Listen to an audio podcast of the June 30, 2022, FDA Drug Safety Communication. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib)…
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns
Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two…
FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging
Listen to an audio podcast of the March 30, 2022 FDA Drug Safety Communication Iodinated Contrast Media
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
Listen to an audio podcast of the February 3, 2022, FDA Drug Safety Communication, FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib). We are…
FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain
Listen to an audio podcast of the January 12, 2022, FDA Drug Safety Communication warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the…
FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
“Listen to FDA Drug Podcast, FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Listen to an audio podcast of the September 1, 2021 FDA Drug Safety Communication on requiring revisions to the Boxed Warning for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about…
FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins
Listen to an audio podcast of the July 20, 2021 FDA Drug Safety Communication, FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises…
FDA warns that vapors from alcohol-based hand sanitizers can have side effects
Listen to an audio podcast of the June 16, 2021 Drug Safety Communication "FDA warns that vapors from alcohol-based hand sanitizers can cause symptoms such as headache, nausea, and dizziness after…
Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis
Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis
Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease
Listen to an audio podcast of the March 31, 2021 FDA Drug Safety Communication that FDA review of studies show a potential increased risk of heart rhythm problems, in patients with heart disease…
FDA warns that abuse and misuse of the OTC nasal decongestant propylhexedrine can lead to serious harm
Listen to an audio podcast of the March 25, 2021 FDA Drug Safety Communication warning that abuse and misuse of the over the counter (OTC) nasal decongestant propylhexedrine (brand name Benzedrex)…
Frequently Asked Questions
FDA Drug Safety Podcasts has published 30 episodes since January 2020, covering topics in Government, Health & Fitness.
FDA Drug Safety Podcasts is currently sporadic with new episodes every 2 months. Average episode length is 3m.
Sign up on Grep.FM to access contact details for FDA Drug Safety Podcasts, including email and social media links.
Similar Podcasts
Think Before Bed
Mark
188 episodes
JamDad Podcast
JamDad Podcast
35 episodes
Dan's Curiosity Shop
Time For Another
5 episodes
Healthcare Matters
Global Healthy Living Foundation
64 episodes
FDA CDER Small Business and Industry Assistance (SBIA) Chronicles
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
12 episodes
Classic Audiobooks Vault
Efrain Cortes
186 episodes